CD96 is commonly expressed on the surface of CD8+ T cells and NK cells and has been implicated as an immune checkpoint inhibitor capable of suppressing IFNG production as well as cytotoxicity and worsening patient prognosis in cancer [46,47]. Here, CD8A is linked to cancer.